Procedural Advantages of a Novel Drug-Eluting Coronary Stent

Procedural Advantages of a Novel Drug-Eluting Coronary Stent With Ultra-Thin Struts and Bioabsorbable Abluminal Polymer Coating in an All-Comers Registry

Status

Completed

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT02881216

Enrollment

814

Registered

2016-08-26

Start date

2015-01-31

Completion date

2016-06-30

Last updated

2016-08-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Coronary Artery Disease

Brief summary

This study sought to compare procedural performance of a new coronary stent generation, that is already available in Germany, with hitherto established current drug-eluting stents.

Interventions

DEVICESynergy Stent

Patients with narrowed coronary artery disease qualifying for PCI were treated with Synergy stent implantation.

DEVICECurrently common drug-eluting stent (DES)

Patients with narrowed coronary artery disease qualifying for PCI were treated with DES implantation (Xience Prime, Resolute Integrity, Promus Element Plus)

Study design

Allocation

NON_RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

18 Years to 99 Years

Healthy volunteers

Inclusion criteria

* CAD for PCI, consecutive patients

Exclusion criteria

* Age under 18 * Bare Metal Stents or Scaffolds

Design outcomes

Primary

Measure	Time frame	Description
In-hospital major cardiac adverse events	One week post-procedure	In-hospital major cardiac adverse events were collected up to one week after procedure throughout the in-patients stay

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026